Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CAMP4 Therapeutics Corporation (CAMP : NSDQ)

• Company Description    CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases. CAMP4 Therapeutics Corporation is based in CAMBRIDGE, Mass. Number of Employees: 55

• Price / Volume Information    Yesterday's Closing Price: $3.48 Daily Weekly Monthly 20 Day Moving Average: 142,381 shares Shares Outstanding: 20.16 (millions) Market Capitalization: $70.16 (millions) Beta: 52 Week High: $12.26 52 Week Low: $1.31 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 16.00% 13.70% 12 Week 113.50% 100.85% Year To Date -33.33% -41.81%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL ONE KENDALL SQUARE BUILDING 1400 WEST 3RD FLOOR - CAMBRIDGE,MA 02139 USA ph: 617-651-8867 fax: - svonderweid@lifesciadvisors.com http://www.camp4tx.com

• General Corporate Information    Officers Josh Mandel-Brehm - Chief Executive Officer and President Steven Holtzman - Chairman Kelly Gold - Chief Financial Officer James Boylan - Director Ingo Chakravarty - Director Peer Information CAMP4 Therapeutics Corporation (CORR.) CAMP4 Therapeutics Corporation (RSPI) CAMP4 Therapeutics Corporation (CGXP) CAMP4 Therapeutics Corporation (BGEN) CAMP4 Therapeutics Corporation (GTBP) CAMP4 Therapeutics Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 13463J101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/20/25 Share - Related Items Shares Outstanding: 20.16 Most Recent Split Date: (:1) Beta: Market Capitalization: $70.16 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/20/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.75 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 74.48% ROE 09/30/25 - - 06/30/25 - - 03/31/25 - - ROA 09/30/25 - - 06/30/25 - -96.92 03/31/25 - -127.48 Current Ratio 09/30/25 - - 06/30/25 - 5.60 03/31/25 - 8.02 Quick Ratio 09/30/25 - - 06/30/25 - 5.60 03/31/25 - 8.02 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - - 06/30/25 - -1,722.08 03/31/25 - -3,428.61 Book Value 09/30/25 - - 06/30/25 - 1.98 03/31/25 - 2.56 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.15 03/31/25 - 0.11

Powered by Zacks Investment Research ©